Peptide Comparison
Tesamorelin vs Tesamorelin + Ipamorelin
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Tesamorelin and Tesamorelin + Ipamorelin share the ghrh / gh-secretagogue classes and carry roughly equivalent evidence (FDA-Approved / FDA-Approved (component)). On the catalogued data layer Tesamorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Tesamorelin's evidence base is currently denser.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Side-by-side
| Tesamorelin | Tesamorelin + Ipamorelin | |
|---|---|---|
| Class | GHRH analog (FDA-approved) | FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend |
| Drug class | Growth Hormone Secretion | Growth Hormone Secretion |
| Mechanism | Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion | Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. |
| Route | SC injection | SC injection |
| Half-life | ~26 min | Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs |
| Dosage (research) | 2 mg SC daily (FDA label) | 1 mg Tesamorelin + 200 mcg Ipamorelin SC nightly (5 nights/wk). Cycle 12-16 weeks on / 4-6 weeks off |
| Evidence tier | FDA-Approved | FDA-Approved (component) |
| Research depth | 127 indexed | — |
| Availability | Prescription | Compounding Restricted |
| Reported risks | Injection site reactions; hyperglycemia; joint pain; edema; elevated IGF-1 | Tesamorelin component carries FDA-label pancreatitis and hyperglycaemia warnings; injection-site reactions; theoretical IGF-1 elevation; cost is high (Tesamorelin compounded form is expensive) |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Tesamorelin or Tesamorelin + Ipamorelin?
Tesamorelin and Tesamorelin + Ipamorelin share the ghrh / gh-secretagogue classes and carry roughly equivalent evidence (FDA-Approved / FDA-Approved (component)). On the catalogued data layer Tesamorelin has a slight edge: more cited sources or efficacy data on file. For most research framings either pick is defensible; Tesamorelin's evidence base is currently denser.
What is the difference between Tesamorelin and Tesamorelin + Ipamorelin?
Tesamorelin is classed as GHRH analog (FDA-approved); Tesamorelin + Ipamorelin is classed as FDA-approved GHRH analog (Tesamorelin) + selective GHRP (Ipamorelin) blend. Reported mechanism: Tesamorelin, Binds pituitary GHRH receptor to stimulate pulsatile endogenous GH secretion; Tesamorelin + Ipamorelin, Tesamorelin's trans-3-hexenoyl modification gives a longer-acting pituitary GHRH-R stimulus than CJC no-DAC, paired with Ipamorelin's GHS-R1a pulse to layer pituitary GH release. The Tesamorelin arm carries the strongest single-agent visceral-fat data (EMERALD); the Ipamorelin arm contributes pulse amplitude without cortisol/prolactin spillover. Reported half-life: Tesamorelin, ~26 min; Tesamorelin + Ipamorelin, Tesamorelin ~26 min (plasma); Ipamorelin ~2 hrs. Routes in published studies: Tesamorelin, SC injection; Tesamorelin + Ipamorelin, SC injection.
Which has stronger evidence, Tesamorelin or Tesamorelin + Ipamorelin?
Tesamorelin and Tesamorelin + Ipamorelin sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Tesamorelin is graded FDA-Approved, with 13 cited sources on its reference page and 127 indexed studies. Tesamorelin + Ipamorelin is graded FDA-Approved (component), with 3 cited sources on its reference page.
Which is more accessible, Tesamorelin or Tesamorelin + Ipamorelin?
Tesamorelin is FDA-approved and Tesamorelin + Ipamorelin is not. Catalog status: Tesamorelin, Prescription; Tesamorelin + Ipamorelin, Compounding Restricted.
Are Tesamorelin and Tesamorelin + Ipamorelin ever combined?
Tesamorelin and Tesamorelin + Ipamorelin appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…